Applied Cognition

Executive Summary

Applied Cognition is a private platform therapeutics company founded in 2018 and headquartered in Redwood City, California. The company is pioneering a novel approach to treating neurodegenerative diseases such as Alzheimer's and Parkinson's by targeting the brain's glymphatic system—a natural waste clearance pathway. Using its proprietary discovery platform, Applied Cognition develops small molecule drugs designed to non-invasively measure and modulate glymphatic function, aiming to enhance the removal of toxic proteins like amyloid-beta and alpha-synuclein. This strategy represents a departure from traditional approaches focused on amyloid or tau, instead addressing the underlying clearance deficit that may contribute to disease progression. The company remains in the preclinical stage, with no disclosed funding rounds or clinical candidates publicly identified. The glymphatic system hypothesis has garnered increasing scientific interest, and Applied Cognition's platform could offer a first-in-class therapeutic modality. However, the approach is unvalidated in humans, and the company faces significant technical and regulatory hurdles, including challenges in measuring glymphatic activity and demonstrating clinical benefit. Its success will depend on securing financing, advancing to IND-enabling studies, and generating proof-of-concept data. At present, Applied Cognition is a high-risk, high-reward opportunity within the neurodegenerative disease space.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round70% success
• Q4 2026IND-Enabling Studies Initiation50% success
• Q2 2026Lead Candidate Nomination80% success